A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
Status:
Completed
Trial end date:
2017-05-02
Target enrollment:
Participant gender:
Summary
This 2-arm study will investigate the safety and tolerability of oseltamivir for the
treatment of influenza in immunocompromised participants and characterize the effects of
oseltamivir in immunocompromised participants on the development of resistant influenza
virus. Eligible immunocompromised participants with laboratory-confirmed influenza will be
randomized to receive either conventional dose (30 milligrams [mg] to 75 mg twice daily
orally [po], depending on age and weight) or double dose (60 mg-150 mg twice daily po
depending on age and weight) olseltamivir for 10 days. Nasal and throat swabs will be taken,
and safety evaluations made, at intervals during the study. The anticipated time on study
medication is 10 days and the anticipated time on study is 40 days.